Kitov’s $35 Million Shares Offering


Haynes and Boone, LLP represented Kitov Pharma in the offering.

Kitov Pharma Ltd. (NASDAQ/TASE: KTOV) executed a registered direct offering of American Depositary Shares (ADSs) and warrants to purchase ADSs that raised gross proceeds of $35 million.

A clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, Kitov intends to use the net proceeds of this offering to fund the development of its oncology drug candidates, acquisition of new assets, and for general working capital purposes.

Haynes and Boone, LLP represented Kitov Pharma with a team led by New York Partner Rick Werner (Picture), co-chair of Haynes and Boone’s Capital Markets and Securities Practice Group, and Jayun Koo, a Partner in the New York Capital Markets and Securities Practice Group. They were assisted by Haynes and Boone lawyers: So Yung Kang and Eloise Rotenberg.

Involved fees earner: So Yung Kang – Haynes and Boone; Jayun Koo – Haynes and Boone; Eloise Rotenberg – Haynes and Boone; Rick Werner – Haynes and Boone;

Law Firms: Haynes and Boone;

Clients: Kitov Pharmaceuticals Holdings;

Author: Ambrogio Visconti